24 certified Labor Condition Applications on file with the U.S. Department of Labor, FY2021–FY2026.
Since September 2025, DOL's Project Firewall opens H-1B investigations without waiting for a complaint. These checkpoints come from Kymera Therapeutics, Inc.'s own public LCA filings (FY2024–FY2026) — the same records an investigator pulls first.
Next end date: 2026-11-08. Employing an H-1B worker past the LCA end date without a new certified LCA is a strict-liability violation — the replacement LCA must be certified before the I-129 extension is filed.
Level I is the entry-level prevailing-wage tier and the band DOL's Project Firewall reviews first for misclassification (senior duties filed at an entry-level wage). The national share is 17%.
Median offered wage is 26% above the DOL prevailing wage across 11 recent certified LCAs. Paying at the floor is lawful, but it invites the question of whether the wage level itself is right.
Each worksite needs its own 10-business-day LCA notice and a PAF record of that posting; a move to a new area of intended employment needs a new LCA before the worker starts there.
No additional recruitment or non-displacement attestations apply.
Public DOL disclosure data can lag actual filings by a quarter. Descriptive only — not legal advice.
Yes — Kymera Therapeutics, Inc. sponsors H-1B workers, with 24 certified LCAs on file (FY2021–FY2026), including 4 in FY2026. The median certified salary is $117,500 (P25 $93,750, P75 $162,500). With a 46% transfer share, this employer actively accepts H-1B transfers. 100% of its certified filings meet or exceed the prevailing wage.
Kymera Therapeutics, Inc. H-1B sponsorship at a glance, from public U.S. DOL LCA disclosure data (FY2021–FY2026).
Certified LCAs are a prerequisite to H-1B petitions, not visa approvals; one LCA can cover multiple workers. Descriptive only — not legal advice.
The shaded band is the middle half of certified salaries (P25–P75); the bar spans the lowest to highest certified salary.
Levels I–IV are DOL prevailing-wage experience tiers; 25% of filings are senior-level (III–IV).
| Fiscal year | Certified | Denied | Withdrawn | Total |
|---|---|---|---|---|
| FY2021 | 5 | 0 | 0 | 5 |
| FY2022 | 3 | 0 | 0 | 3 |
| FY2023 | 5 | 0 | 0 | 5 |
| FY2024 | 2 | 0 | 0 | 2 |
| FY2025 | 5 | 0 | 0 | 5 |
| FY2026 | 4 | 0 | 0 | 4 |
Case dispositions from the U.S. DOL OFLC disclosure files. Withdrawn are LCAs that were certified and later withdrawn by the employer; they still count toward Total.
| Job title | Salary | Level | Location | Filed | Status |
|---|---|---|---|---|---|
Director, Late Stage Formulations Development I-200-26173-039470 | $230,000/yr | II | Watertown, MA | Jun 22, 2026 | Certified |
Associate Scientist, Cellular Pharmacology I-200-26159-993336 | $113,000/yr | I | Watertown, MA | Jun 08, 2026 | Certified |
Associate Scientist, Discovery Biology I-200-26121-857844 | $125,715/yr | II | Watertown, MA | May 01, 2026 | Certified |
Senior Director, Pharmacovigilance Operations I-200-26069-693805 | $280,000/yr | IV | Watertown, MA | Mar 10, 2026 | Certified |
Principal Scientist, Biological Sciences I-200-25232-254718 | $160,000/yr | II | Watertown, MA | Aug 20, 2025 | Certified |
Scientist, Computational Biology I-200-25230-249170 | $130,000/yr | II | Watertown, MA | Aug 18, 2025 | Certified |
Associate Director, Translational Medicine I-200-25213-216778 | $190,000/yr | II | Watertown, MA | Aug 01, 2025 | Certified |
Associate Director, Bioanalytical I-200-25169-107603 | $185,000/yr | III | Watertown, MA | Jun 18, 2025 | Certified |
Scientist, Discovery Biology I-200-25071-770310 | $120,000/yr | II | Watertown, MA | Mar 12, 2025 | Certified |
Senior Scientist, Proteomics I-200-24099-863701 | $140,000/yr | III | Watertown, MA | Apr 08, 2024 | Certified |
Associate Scientist, Platform Biology I-200-23346-560151 | $110,000/yr | II | Watertown, MA | Dec 12, 2023 | Certified |
Senior Scientist, In Vitro Pharmacology I-200-23219-242738 | $135,000/yr | III | Watertown, MA | Aug 07, 2023 | Certified |
Senior Research Associate, Platform Biology I-200-23128-000951 | $90,000/yr | I | Watertown, MA | May 08, 2023 | Certified |
Research Associate II, Cellular Assays I-200-23128-000994 | $75,000/yr | I | Watertown, MA | May 08, 2023 | Certified |
Associate Director, Translational Medicine I-200-22276-508139 | $170,000/yr | II | Watertown, MA | Oct 03, 2022 | Certified |
Scientist II, Oncology Biology I-200-22133-169619 | $115,000/yr | II | Watertown, MA | May 13, 2022 | Certified |
Associate Scientist, Computational Biology I-200-22133-169709 | $85,000/yr | II | Watertown, MA | May 13, 2022 | Certified |
Associate Scientist, Platform Biology I-200-22118-117525 | $95,000/yr | II | Watertown, MA | Apr 28, 2022 | Certified |
Scientist, Proteomics I-200-21127-297140 | $82,555/yr | II | Watertown, MA | May 07, 2021 | Certified |
Scientist, Platform Biology I-200-21041-066935 | $82,555/yr | II | Watertown, MA | Feb 09, 2021 | Certified |
Scientist, Oncology Biology I-200-21032-046114 | $105,872/yr | III | Watertown, MA | Feb 01, 2021 | Certified |
One row per LCA case (its latest version), from U.S. DOL OFLC disclosure data. Salaries are the offered wage, converted to a yearly figure. Certified LCAs are not visa approvals.
Worker positions by LCA filing purpose, summed across FY2021–FY2026 disclosure records.
Most active filing months: May and Feb — useful for timing transfer conversations.
Attestations from the employer's own LCA filings (Form ETA-9035), as disclosed by the U.S. DOL.
1 state · 1 city
The same DOL data on this page is what every H-1B sponsor must track for each worker. ElevateStaffing.ai automates it end-to-end:
Get the private PAF / LCA gap check for your own filings — free, one business day — then let ElevateStaffing.ai keep every LCA, PAF, I-9 and I-983 deadline audit-ready.
Get my private gap check →